CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04534283
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:18.533898+00:00
Published At: 2024-08-07T00:00:00+00:00
Record Updated At: 2024-08-07
Results Posted At: 2024-08-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cancer", "Cancer Metastatic", "BRAF V600E", "MEK1 Gene Mutation", "MEK2 Gene Mutation", "ERK Mutation", "RAF1 Gene Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-08-07"
protocolSection.identificationModule.nctId: "NCT04534283"
protocolSection.identificationModule.officialTitle: "A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1."
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-08-07"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.